Visceral Pain Treatment Market Synopsis:

Visceral Pain Treatment Market Size Was Valued at USD 14.6 Billion in 2023, and is Projected to Reach USD 24.25 Billion by 2032, Growing at a CAGR of 5.8 % From 2024-2032.

The visceral and somatic pain products and therapies entail pain arising from the internal organs resulting from IBS, IBD, interstitial cystitis, and chronic pelvic pain and the like, whereas pain due to damaged tissue Visceral pain treatment market can also be categorised in the pharmacological based treatment including the pain relievers, antidepressants and antispasmodics and nonpharmacological which include the cognitive behaviour therapy, acupuncture and physical therapy.

The market of visceral pain treatment is gradually emerging as a larger number of people are affected by chronic diseases that accompany visceral pain. People are becoming more aware of the diseases that cause gastrointestinal and pelvic pain and as such more patients are already accessing the correct treatment. In addition, the transition from traditional therapy to a therapy that progresses unique patient therapy is likely to fuel the market in the future fiscal years.

Rising health care cost, rising population with diseases, and better diagnosing techniques. Patients are now presenting to the doctors’ offices with chronic visceral pain disorders, hence the necessity of treatments. At the same time, the enhancement of the patient’s awareness of diseases such as IBS, Crohn’s disease, and interstitial cystitis has gradually built up the sound foundation for the market development, and thus encouraging companies to increase the investment in R&AD of new and efficient therapeutic methods.

Visceral Pain Treatment Market Growth Analysis & Forecast (2024-2032)

Visceral Pain Treatment Market Trend Analysis:

Increasing Focus on Pain Modifiers

  • The main trend which forms in the spectators of the visceral pain treatment market is a change to produce pain modifiers, which target causes of visceral pain and decreased reliance on symptoms. These therapies are designed with the full intention of assisting the patient to eliminate his pain since they influence the very structures that are used in the transmission of pain signal in the body and reprogramming the body’s response to the signals being transmitted.

  • More often than not there is a transition from the pharmacological progression of the disease to the clinical ones because different neurological mechanisms are involved in visceral pain. Additional understanding of the parts of the nervous system of pain is significant for the identification of treatment approaches based on nerve block injections, neuromodulators, and biologics, which according to patients have high rates of intensity and frequency of pain reduction.

Emergence of Non-Pharmacological Treatment Options

  • One of the trends in the market of visceral pain treatment is concerned with the shift in focus towards the non-pharmacological approach towards the diseased. Due to the detrimental impacts and the various dangers of dependency in long-term medication usage as a major concern, patients and the health care providers are embracing non-drug treatment of the patients’ disorders including physical therapy,

  • Acupuncture therapy, cognitive behavioral therapy and biofeedback therapy. Such approaches are particularly effective in patients who have to minimize visceral pain but are not willing to take drugs on a daily basis. In the field of Visceral pain, non-pharmacological treatments appear prominently as a new way to cope with the pain, thus as the quantity of studies on the effectiveness of the mentioned therapies increases, the public can anticipate better outcomes of non-pharmacological pains.

Visceral Pain Treatment Market Segment Analysis:

Visceral Pain Treatment Market is Segmented on the basis of Drug Type, Indication, Distribution Channel, and Region

By Drug Type, Pain modifiers segment is expected to dominate the market during the forecast period

  • According to the company, out of all such segments the pain modifiers segment shall play a major role in the visceral pain treatment market in the given forecast period. New branches are known as pain modulators – a set of permissible methods that make it possible to change the functional condition of the nervous system so that the patient will not feel the pain signal. Most of these therapies address issues of tissue injury as a function of altering the pain message rather than the painful feelings themselves.

  • There is a growing use of neuromodulators, nerve blocks and biologics likely because they offer more prolonged durations of effect and may be utilised in more specific cases. Due to advancements in clinical research in the near future, and the move from global modifiers to more directed therapies, it is expected that the segment would grow at a very fast pace in the upcoming few years establishing the segment as the leader in the market.

By Indication, Irritable Bowel Syndrome segment expected to held the largest share

  • The market for visceral pain treatment is in turning out to be a colossal market and is set out to locate its largest market share in the irritable bowel syndrome IBS segment in the predetermined timeframe. Ibs is among the most common gastrointestinal disorders which do not cease to interfere with the quality of life in individuals experiencing it through, constipation and/or diarrhea, bloating and /or abdominal pain or cramps.

  • This rather painful and potentially awkward situation is also increasing with modern living, and as more people learn about Fibromyalgia and the diagnostic tests available, those with the condition are actively seeking treatment. Targeted medications with sufficient evidence to change the IBS pathophysiology are antispasmodics, antidepressants, and targeted gut therapies and all show a rising trend in use. This segment leverages on better diagnostic rate, and the growth in the number of patients seeking treatment for IBS to meet a broad pipeline of drug target therapies for visceral pain linked to IBS.

Visceral Pain Treatment Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

  • Out of all the regions it is forcasted that North America will display the largest market size of the visceral pain treatment during the period under study attributed to highly developed health care industry, sound research and development activities together with high health care expenditure levels. In the area specially the America primitive has a health care infrastructure, people’s Health technology health sector access to health advanced technologies and high health care density. A survey shows that a huge number of people suffering from chronic visceral pain due to fibromyalgia, IBS, interstitial cystitis or Crohn’s disease will lead to a higher use of treatment.

  • The highest across the globe as more investment goes into research and development in the pain management niche. The pharma firms and research institutions in North America are present at the moment on a high aerobic R & D activity towards the development of novel therapeutic modalities in visceral pain which might be directed towards the causative factor of the said pain. Better patient and provider awareness of the importance of quick and effective treatment is promoting the requirement for selective drugs that offer sustained relief.

Active Key Players in the Visceral Pain Treatment Market

  • Astellas Pharma (Japan)
  • Biogen (United States)
  • Bristol-Myers Squibb (United States)
  • Eli Lilly and Company (United States)
  • GlaxoSmithKline (United Kingdom)
  • Grunenthal (Germany)
  • Janssen Pharmaceuticals (United States)
  • Johnson & Johnson (United States)
  • Mallinckrodt Pharmaceuticals (Ireland)
  • Merck & Co. (United States)
  • Novartis (Switzerland)
  • Pfizer Inc. (United States)
  • Reckitt Benckiser (United Kingdom)
  • Sanofi (France)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Other Active Players
 

Global Visceral Pain Treatment Market

Base Year:

2023

Forecast Period:

2024-2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 14.6 Billion

Forecast Period 2024-32 CAGR:

 5.8%

Market Size in 2032:

USD 24.25 Billion

Segments Covered:

By Drug Type
  • Pain modifiers
  • Tricyclic Anticonvulsant
  • Tricyclic Antidepressants
  • Analgesics
  •  Narcotics
  • NSAID
  • Others

By Indication
  • Chronic Prostatitis
  • Interstitial Cystitis
  • Crohn’s Disease
  • Irritable Bowel Syndrome

By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Channels

By Region
  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, Netherlands, Italy, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC)
  • Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:
  • Increasing prevalence of gastrointestinal and pelvic pain disorders, leading to higher demand for effective treatments.

Key Market Restraints:
  • The high cost of specialised treatments and medications

Key Opportunities:
  • Growth in non-pharmacological treatments, offering a more holistic approach to managing visceral pain

Companies Covered in the Report:
  • Astellas Pharma (Japan), Biogen (United States), Bristol-Myers Squibb (United States), Eli Lilly and Company (United States), GlaxoSmithKline (United Kingdom), and Other Active Players.

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Visceral Pain Treatment Market by Component
 4.1 Visceral Pain Treatment Market Snapshot and Growth Engine
 4.2 Visceral Pain Treatment Market Overview
 4.3 Software
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Software: Geographic Segmentation Analysis
 4.4 Service
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Service: Geographic Segmentation Analysis
 4.5 Hardware
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Hardware: Geographic Segmentation Analysis

Chapter 5: Visceral Pain Treatment Market by Application
 5.1 Visceral Pain Treatment Market Snapshot and Growth Engine
 5.2 Visceral Pain Treatment Market Overview
 5.3 Movies
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Movies: Geographic Segmentation Analysis
 5.4 TV Gaming Advertisements
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 TV Gaming Advertisements: Geographic Segmentation Analysis

Chapter 6: Visceral Pain Treatment Market by Technology
 6.1 Visceral Pain Treatment Market Snapshot and Growth Engine
 6.2 Visceral Pain Treatment Market Overview
 6.3 AI AR
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 AI AR: Geographic Segmentation Analysis

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Benchmarking
  7.1.2 Visceral Pain Treatment Market Share by Manufacturer (2023)
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Mergers and Acquisitions  
 7.2 ASTELLAS PHARMA (JAPAN)
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Role of the Company in the Market
  7.2.5 Sustainability and Social Responsibility
  7.2.6 Operating Business Segments
  7.2.7 Product Portfolio
  7.2.8 Business Performance
  7.2.9 Key Strategic Moves and Recent Developments
  7.2.10 SWOT Analysis
 7.3 BIOGEN (UNITED STATES)
 7.4 BRISTOL-MYERS SQUIBB (UNITED STATES)
 7.5 ELI LILLY AND COMPANY (UNITED STATES)
 7.6 GLAXOSMITHKLINE (UNITED KINGDOM)
 7.7 GRUNENTHAL (GERMANY)
 7.8 JANSSEN PHARMACEUTICALS (UNITED STATES)
 7.9 JOHNSON & JOHNSON (UNITED STATES)
 7.10 MALLINCKRODT PHARMACEUTICALS (IRELAND)
 7.11 MERCK & CO. (UNITED STATES)
 7.12 NOVARTIS (SWITZERLAND)
 7.13 PFIZER INC. (UNITED STATES)
 7.14 RECKITT BENCKISER (UNITED KINGDOM)
 7.15 SANOFI (FRANCE)
 7.16 TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
 7.17 OTHER ACTIVE PLAYERS

Chapter 8: Global Visceral Pain Treatment Market By Region
 8.1 Overview
 8.2. North America Visceral Pain Treatment Market
  8.2.1 Key Market Trends, Growth Factors and Opportunities
  8.2.2 Top Key Companies
  8.2.3 Historic and Forecasted Market Size by Segments
  8.2.4 Historic and Forecasted Market Size By Component
  8.2.4.1 Software
  8.2.4.2 Service
  8.2.4.3 Hardware
  8.2.5 Historic and Forecasted Market Size By Application
  8.2.5.1 Movies
  8.2.5.2 TV Gaming Advertisements
  8.2.6 Historic and Forecasted Market Size By Technology
  8.2.6.1 AI AR
  8.2.7 Historic and Forecast Market Size by Country
  8.2.7.1 US
  8.2.7.2 Canada
  8.2.7.3 Mexico
 8.3. Eastern Europe Visceral Pain Treatment Market
  8.3.1 Key Market Trends, Growth Factors and Opportunities
  8.3.2 Top Key Companies
  8.3.3 Historic and Forecasted Market Size by Segments
  8.3.4 Historic and Forecasted Market Size By Component
  8.3.4.1 Software
  8.3.4.2 Service
  8.3.4.3 Hardware
  8.3.5 Historic and Forecasted Market Size By Application
  8.3.5.1 Movies
  8.3.5.2 TV Gaming Advertisements
  8.3.6 Historic and Forecasted Market Size By Technology
  8.3.6.1 AI AR
  8.3.7 Historic and Forecast Market Size by Country
  8.3.7.1 Russia
  8.3.7.2 Bulgaria
  8.3.7.3 The Czech Republic
  8.3.7.4 Hungary
  8.3.7.5 Poland
  8.3.7.6 Romania
  8.3.7.7 Rest of Eastern Europe
 8.4. Western Europe Visceral Pain Treatment Market
  8.4.1 Key Market Trends, Growth Factors and Opportunities
  8.4.2 Top Key Companies
  8.4.3 Historic and Forecasted Market Size by Segments
  8.4.4 Historic and Forecasted Market Size By Component
  8.4.4.1 Software
  8.4.4.2 Service
  8.4.4.3 Hardware
  8.4.5 Historic and Forecasted Market Size By Application
  8.4.5.1 Movies
  8.4.5.2 TV Gaming Advertisements
  8.4.6 Historic and Forecasted Market Size By Technology
  8.4.6.1 AI AR
  8.4.7 Historic and Forecast Market Size by Country
  8.4.7.1 Germany
  8.4.7.2 UK
  8.4.7.3 France
  8.4.7.4 The Netherlands
  8.4.7.5 Italy
  8.4.7.6 Spain
  8.4.7.7 Rest of Western Europe
 8.5. Asia Pacific Visceral Pain Treatment Market
  8.5.1 Key Market Trends, Growth Factors and Opportunities
  8.5.2 Top Key Companies
  8.5.3 Historic and Forecasted Market Size by Segments
  8.5.4 Historic and Forecasted Market Size By Component
  8.5.4.1 Software
  8.5.4.2 Service
  8.5.4.3 Hardware
  8.5.5 Historic and Forecasted Market Size By Application
  8.5.5.1 Movies
  8.5.5.2 TV Gaming Advertisements
  8.5.6 Historic and Forecasted Market Size By Technology
  8.5.6.1 AI AR
  8.5.7 Historic and Forecast Market Size by Country
  8.5.7.1 China
  8.5.7.2 India
  8.5.7.3 Japan
  8.5.7.4 South Korea
  8.5.7.5 Malaysia
  8.5.7.6 Thailand
  8.5.7.7 Vietnam
  8.5.7.8 The Philippines
  8.5.7.9 Australia
  8.5.7.10 New Zealand
  8.5.7.11 Rest of APAC
 8.6. Middle East & Africa Visceral Pain Treatment Market
  8.6.1 Key Market Trends, Growth Factors and Opportunities
  8.6.2 Top Key Companies
  8.6.3 Historic and Forecasted Market Size by Segments
  8.6.4 Historic and Forecasted Market Size By Component
  8.6.4.1 Software
  8.6.4.2 Service
  8.6.4.3 Hardware
  8.6.5 Historic and Forecasted Market Size By Application
  8.6.5.1 Movies
  8.6.5.2 TV Gaming Advertisements
  8.6.6 Historic and Forecasted Market Size By Technology
  8.6.6.1 AI AR
  8.6.7 Historic and Forecast Market Size by Country
  8.6.7.1 Turkiye
  8.6.7.2 Bahrain
  8.6.7.3 Kuwait
  8.6.7.4 Saudi Arabia
  8.6.7.5 Qatar
  8.6.7.6 UAE
  8.6.7.7 Israel
  8.6.7.8 South Africa
 8.7. South America Visceral Pain Treatment Market
  8.7.1 Key Market Trends, Growth Factors and Opportunities
  8.7.2 Top Key Companies
  8.7.3 Historic and Forecasted Market Size by Segments
  8.7.4 Historic and Forecasted Market Size By Component
  8.7.4.1 Software
  8.7.4.2 Service
  8.7.4.3 Hardware
  8.7.5 Historic and Forecasted Market Size By Application
  8.7.5.1 Movies
  8.7.5.2 TV Gaming Advertisements
  8.7.6 Historic and Forecasted Market Size By Technology
  8.7.6.1 AI AR
  8.7.7 Historic and Forecast Market Size by Country
  8.7.7.1 Brazil
  8.7.7.2 Argentina
  8.7.7.3 Rest of SA

Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies

Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research

Global Visceral Pain Treatment Market

Base Year:

2023

Forecast Period:

2024-2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 14.6 Billion

Forecast Period 2024-32 CAGR:

 5.8%

Market Size in 2032:

USD 24.25 Billion

Segments Covered:

By Drug Type
  • Pain modifiers
  • Tricyclic Anticonvulsant
  • Tricyclic Antidepressants
  • Analgesics
  •  Narcotics
  • NSAID
  • Others

By Indication
  • Chronic Prostatitis
  • Interstitial Cystitis
  • Crohn’s Disease
  • Irritable Bowel Syndrome

By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Channels

By Region
  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, Netherlands, Italy, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC)
  • Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:
  • Increasing prevalence of gastrointestinal and pelvic pain disorders, leading to higher demand for effective treatments.

Key Market Restraints:
  • The high cost of specialised treatments and medications

Key Opportunities:
  • Growth in non-pharmacological treatments, offering a more holistic approach to managing visceral pain

Companies Covered in the Report:
  • Astellas Pharma (Japan), Biogen (United States), Bristol-Myers Squibb (United States), Eli Lilly and Company (United States), GlaxoSmithKline (United Kingdom), and Other Active Players.

Frequently Asked Questions :

What would be the forecast period in the Visceral Pain Treatment Market research report?
The forecast period in the Visceral Pain Treatment Market research report is 2024-2032.
Who are the key players in the Visceral Pain Treatment Market?
Astellas Pharma (Japan), Biogen (United States), Bristol-Myers Squibb (United States), Eli Lilly and Company (United States), GlaxoSmithKline (United Kingdom), Grunenthal (Germany), Janssen Pharmaceuticals (United States), Johnson & Johnson (United States), Mallinckrodt Pharmaceuticals (Ireland), Merck & Co. (United States), Novartis (Switzerland), Pfizer Inc. (United States), Reckitt Benckiser (United Kingdom), Sanofi (France), Teva Pharmaceutical Industries Ltd. (Israel), and Other Active Players
What are the segments of the Visceral Pain Treatment Market?
The Visceral Pain Treatment Market is segmented into Drug Type, Indication, Distribution Channel and region. By Drug Type, the market is categorized into Pain modifiers, Tricyclic Anticonvulsant Tricyclic Antidepressants, Analgesics Narcotics, NSAID Others. By Indication, the market is categorized into Chronic Prostatitis, Interstitial Cystitis, Crohn’s Disease Irritable Bowel Syndrome. By Distribution Channel, the market is categorized into Hospital Pharmacy Retail Pharmacy Online Channels. By region, it is analyzed across North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, Netherlands, Italy, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA).
What is the Visceral Pain Treatment Market?
The visceral and somatic pain products and therapies entail pain arising from the internal organs resulting from IBS, IBD, interstitial cystitis, and chronic pelvic pain and the like, whereas pain due to damaged tissue and Visceral pain is pain as a result of an injury to the internal organs making the patients so so uncomfortable and inconvenienced. Visceral pain treatment market can also be categorised in the pharmacological based treatment including the pain relievers, antidepressants and antispasmodics and nonpharmacological which include the cognitive behaviour therapy, acupuncture and physical therapy. From experience laudable goals of the market is to provide substandard solutions that would be able to reduce incidents, gravities and impacts of visceral pain on the patient.
How big is the Visceral Pain Treatment Market?
Visceral Pain Treatment Market Size Was Valued at USD 14.6 Billion in 2023, and is Projected to Reach USD 24.25 Billion by 2032, Growing at a CAGR of 5.8% From 2024-2032.